Cargando…
Cannabinoids in neurologic and mental disease /
The application of cannabis sativa for the treatment of neurologic and mental disease is expanding. Cannabinoids in Neurologic and Mental Disease collects and presents for the first time recent research involving the use of pharmacological cannabinoids for the treatment of neurodegenerative and neur...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Elsevier Inc.,
[2015]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn900781293 | ||
| 003 | OCoLC | ||
| 005 | 20231120111937.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 150127s2015 ne ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d IDEBK |d UIU |d OPELS |d EBLCP |d OCLCF |d CDX |d DEBSZ |d YDXCP |d ABH |d FEM |d VGM |d OCLCO |d MERER |d OCLCO |d OCLCQ |d YDX |d OCLCO |d OCLCA |d MERUC |d OCLCO |d OCLCA |d UUM |d DEBBG |d U3W |d OCLCO |d D6H |d AU@ |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d UKMGB |d OCLCQ |d OCLCO |d OCLCA |d S2H |d OCLCO |d OCLCQ |d OCLCO | ||
| 066 | |c (S | ||
| 015 | |a GBB4F3888 |2 bnb | ||
| 016 | 7 | |a 016991607 |2 Uk | |
| 019 | |a 968083833 |a 969053239 | ||
| 020 | |a 9780124171244 |q (electronic bk.) | ||
| 020 | |a 0124171249 |q (electronic bk.) | ||
| 020 | |z 9780124170414 | ||
| 035 | |a (OCoLC)900781293 |z (OCoLC)968083833 |z (OCoLC)969053239 | ||
| 050 | 4 | |a RM666.C266 | |
| 060 | 4 | |a WL 358.5 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.7/827 |2 23 |
| 245 | 0 | 0 | |a Cannabinoids in neurologic and mental disease / |c edited by Liana Fattore. |
| 264 | 1 | |a Amsterdam : |b Elsevier Inc., |c [2015] | |
| 264 | 4 | |c �2015 | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Online resource; title from PDF title page (ScienceDirect, viewed February 16, 2015). | |
| 520 | |a The application of cannabis sativa for the treatment of neurologic and mental disease is expanding. Cannabinoids in Neurologic and Mental Disease collects and presents for the first time recent research involving the use of pharmacological cannabinoids for the treatment of neurodegenerative and neuroinflammatory disease. The neurologic application of cannabinoid therapy builds upon psychiatric and psychological use for the treatment of a variety of core mental disorders. This comprehensive reference on the known uses of cannabinoids will be useful for clinical neurologists, neuroscience and clinical neuroscience researchers, clinical psychologists and psychiatrists and the general medical community. A comprehensive reference on the clinical uses of cannabinoids for treating major neurologic and mental diseases Detailed coverage of cannabinoid use for neuroinflammatory and neurodegenerative disease including Multiple Sclerosis, Epilepsy, Huntington's disease, Parkinson's disease, and Alzheimer's disease Detailed coverage of cannabinoid use for major psychiatric and psychological diseases and disorders including schizophrenia, bipolar disorders, Tourette's syndrome, and post-traumatic stress disorder (PTSD). | ||
| 505 | 0 | |6 880-01 |a Front Cover -- Cannabinoids in Neurologic and Mental Disease -- Copyright Page -- Contents -- Preface -- List of Contributors -- The ever-expanding world of the endocannabinoids: A concise introduction -- The Endocannabinoid System: Discovery and Early Definitions -- Cannabinoids -- Cannabinoid Receptors -- Endocannabinoids -- Specific and Less Specific Metabolic Routes and Trafficking Mechanisms for Endocannabinoids -- Redundancy and Complexity in Endocannabinoid Targets and Metabolic Enzymes -- Endocannabinoid-Related Mediators and their Targets -- Conclusions: the "Endocannabinoidome" and How to Manage it -- References -- 1 Role of the endocannabinoids in neuroinflammatory and neurodegenerative disorders -- 1 Cannabinoids for the treatment of neuroinflammation -- Neuroinflammation -- Endocannabinoid System Elements in Glial Cells -- Glial Functions and Their Modulation by Cannabinoids -- Astrocyte Functions -- Microglial Functions -- Production and release of cytotoxic molecules -- Migration -- Proliferation and phagocytosis -- Concluding Remarks -- Acknowledgments -- References -- 2 Endocannabinoids and Alzheimer's disease -- Introduction -- Alzheimer's Disease -- The Endocannabinoid System as a Therapeutic Target -- The Endocannabinoid System in Alzheimer's Disease -- Cannabinoids and Neuroinflammation -- Cannabinoids and Oxidative Stress -- Cannabinoids and Excitotoxicity -- Cannabinoids and Neurogenesis -- Conclusions -- References -- 3 Cannabinoids in Parkinson's disease -- Parkinson's Disease -- The Endocannabinoid System in the Normal Basal Ganglia -- Endocannabinoid System Dysregulation in PD -- Clinical Trials of Cannabinoid Drugs in PD Patients -- Potential of the Endocannabinoid System as a Target for Alleviation of Motor Symptoms -- Potential of the Endocannabinoid System as a Target for Alleviation of Drug-Induced Side Effects. | |
| 505 | 8 | |a Endocannabinoid Signaling in ALS -- Treatments with Cannabinoids in Preclinical Models of ALS -- Treatments with Cannabinoids in Clinical Studies with ALS Patients -- Concluding Remarks and Future Perspectives -- Acknowledgments -- References -- 6 Endocannabinoids and epilepsy -- Introduction -- ECS Regulates Excitatory Neuronal Synaptic Transmission -- Alterations in the ECS in Seizures and Epilepsy -- Reorganization of CB1 Receptor Expression and Function in Pilocarpine-Induced Temporal Lobe Epilepsy -- Other Experimental Findings -- Alterations in the ECS in Human Temporal Lobe Epilepsy -- Do Alterations in CB1 Receptors within the IML of the Dentate Gyrus Contribute to TLE? -- Therapeutic Potential of Modulating the ECS in Seizures and Epilepsy -- The Phytocannabinoids -- Targeting CB1 Receptors in Seizures and Epilepsy -- CB1 Receptor Agonists in Adjunctive AED Therapy -- Targeting Endocannabinoid Degradation for Seizure Control -- CB1 Receptor Antagonism as a Prophylactic Treatment for Seizures and Epilepsy -- ECS Interaction with Other Brain Systems in Seizure and Epilepsy -- Cannabinoid-Based Medicines: Implications for their Prolonged use in Clinical Seizures and Epilepsy -- Conclusion and Future Directions -- Acknowledgments -- References -- 7 Endocannabinoids and migraine -- Endocannabinoid System and Migraine -- Migraine Pathogenesis -- Cortical Spreading Depression -- Endocannabinoids and Migraine -- Clinical Data -- Experimental Data -- Studies with neurovascular models of migraine -- Model of Nitroglycerin -- Studies with Electrical Dural Stimulation and Cutaneous Facial Receptive Field Activation of the Ophthalmic Division of the ... -- Studies with vascular models of migraine -- Effect of Cannabinoid Receptor Activation on Cortical Spreading Depression -- Potential Sites and Mechanisms of Action of ECs. | |
| 650 | 0 | |a Cannabinoids. | |
| 650 | 0 | |a Mental illness |x Alternative treatment. | |
| 650 | 1 | 2 | |a Cannabinoids |x therapeutic use |0 (DNLM)D002186Q000627 |
| 650 | 1 | 2 | |a Nervous System Diseases |x drug therapy |0 (DNLM)D009422Q000188 |
| 650 | 2 | 2 | |a Mental Disorders |x drug therapy |0 (DNLM)D001523Q000188 |
| 650 | 2 | |a Cannabinoids |0 (DNLM)D002186 | |
| 650 | 6 | |a Cannabino�ides. |0 (CaQQLa)201-0078335 | |
| 650 | 6 | |a Maladies mentales |x M�edecines parall�eles. |0 (CaQQLa)201-0269617 | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Cannabinoids |2 fast |0 (OCoLC)fst00845733 | |
| 650 | 7 | |a Mental illness |x Alternative treatment |2 fast |0 (OCoLC)fst01016548 | |
| 700 | 1 | |a Fattore, Liana, |e editor. | |
| 776 | 0 | 8 | |i Print version: |z 9780124170414 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780124170414 |z Texto completo |
| 880 | 8 | |6 505-00/(S |a Potential of the Endocannabinoid System as a Disease Modifying Target -- The Effect of Cannabinoid Drugs on α-Synucleinopathy -- The Neuroprotective Potential of Cannabinoid Drugs -- The Anti-Inflammatory Potential of Cannabinoid Drugs -- Concluding Remarks -- References -- 4 Cannabinoids and Huntington's disease -- The Endocannabinoid System -- Components, Working Mechanism, and Distribution -- Physiological Role of the ECS within the CNS -- Endocannabinoid Signaling and Huntington's Disease -- Huntington's Disease -- The ECS and the Control of Motor Behavior -- Endocannabinoids and CB1 receptors in basal ganglia structures -- Functional interaction between ECS and dopamine in basal ganglia circuits -- The ECS and Neuroinflammation -- Alterations of the ECS in HD -- Therapeutic Potential of Endocannabinoids in HD -- Effects on Motor Symptoms -- Effects on Pathogenesis -- Future Perspectives and Needs -- Relevance of Molecular Imaging of the ECS in HD -- Imaging of the Brain CB1 Receptor -- Currently available CB1 receptor radioligands for human CB1 receptor imaging: "second generation compounds" -- [11C]JHU75528 or [11C]OMAR -- [11C]MePPEP and [18F]FMPEP-d2 -- [18F]MK9470 -- Imaging of the Brain CB2 Receptor -- Triaryl bis-sulfones -- Indole derivate -- Quinoline derivates -- Thiozole derivates -- PET Imaging of CB1 and CB2 Receptors in HD -- General Conclusion -- References -- 5 Endocannabinoids and amyotrophic lateral sclerosis -- Amyotrophic Lateral Sclerosis -- Epidemiological and Clinical Aspects -- Neuropathological Aspects -- Glutamate toxicity -- Glial activation and local neuroinflammation -- Oxidative stress -- Defects in RNA transcription, processing, and stability -- Protein deposition and aggregation -- Mitochondrial dysfunction -- Impairment in axonal transport -- Treatments Approved and/or Under Investigation -- Cannabinoids and ALS. | |
| 880 | 8 | |6 505-00/(S |a Effects on the Serotonin System -- Effects on the NMDA/glutamate System -- Effects on Inflammatory Molecules -- Limitations -- New Potential Therapeutic Approaches -- Inhibitors of Catabolism -- CB2 Receptor Agonists -- Conclusions -- References -- 2 Role of the endocannabinoids in psychological and psychiatric disorders -- 8 Cannabinoids and schizophrenia -- Introduction -- Endocannabinoid System and Schizophrenia -- Cannabis and Schizophrenia -- Cannabidiol and Schizophrenia -- Conclusions -- References -- 9 Cannabinoids and bipolar disorder -- Introduction -- Prevalence of Cannabis use in Bipolar Disorder -- Clinical Correlates of Cannabis Use in Bipolar Disorder -- Age at Onset -- Course of Illness -- Mood and psychotic symptoms -- Sequence of onsets -- Suicide -- Comorbid disorders -- Psychosocial functioning -- Cannabis Use and Neurocognition in Bipolar Disorder -- Cannabis and Cognition -- Neurocognitive Deficits in Bipolar Disorder -- Cannabis and Cognition in Bipolar Disorder -- Impact on Diagnosis and Treatment -- Diagnosis -- Treatment -- Conclusions -- References -- 10 Cannabinoids and the Tourette syndrome -- Tourette Syndrome -- Definition and Clinic -- Epidemiology, Genetics, and Pathology -- Therapy -- Alternative Treatments -- Medicinal Use of Cannabinoid-Based Medicines -- Effects of Cannabis Sativa L. in Patients with Tourette Syndrome -- Case Reports -- Results from a Prospective Survey -- Controlled Trials -- Effects of Δ9-Tetrahydrocannabinol in Patients with Tourette Syndrome -- Uncontrolled Single-Case Studies -- Randomized Controlled Trials Using THC -- The Neurochemistry of Tourette Syndrome: Which Role Does the CB1 Receptor System Play-- Adverse Effects -- Practical Aspects for the Treatment of Patients with TS with CBM -- Conclusions -- References. | |
| 880 | 8 | |6 505-01/(S |a 11 The role of endocannabinoid function in posttraumatic stress disorder: Modulating the risk phenotype and rendering effec ... -- Introduction -- Overview of the Endocannabinoid System -- Endocannabinoid Function in PTSD -- Role of the Endocannabinoid System in Modulating Risk for PTSD -- Negative Emotionality: A Key Role for Endocannabinoid Signaling in PTSD -- An Emerging Focus on Reward Dysfunction in PTSD -- PTSD and Externalizing: Endocannabinoid Function and Control -- Experience-Dependent Changes in PTSD: Endocannabinoids and Synaptic Plasticity -- Rendering Acute Trauma Into Symptoms: Animal Models of Fear -- Long-Term Endocannabinoid Adaptations: The Legacy of Early Life Adversity -- PTSD and Cannabis Use: Endocannabinoid Function in an Interdependent Trajectory -- A Shared Diathesis -- Self-Medicating with Cannabis -- The Endocannabinoid System in the Treatment of PTSD: A Cautionary Tale -- Future Directions -- Etiologic Research -- Therapeutic Implications -- Policy and Law -- References -- 12 Cannabinoids and drug addiction -- Drug Abuse and Addiction -- The Modulating Role of the Endocannabinoid System in Drug-Induced Reward -- Associated Polymorphisms in the Cannabinoid CB1 Receptor (CNR1) and Fatty-acid Amide Hydrolase (FAAH) Genes -- CB1 Receptor and FAAH Knockout Mice in Cannabinoid Addiction Research -- The Endocannabinoid System in Human Drug Addiction -- Cannabis -- Alcohol -- Nicotine -- Cocaine -- Amphetamines -- Opioids -- Conclusions -- References -- 13 Cannabinoids and appetite (dys)regulation -- Introduction -- Early Clinical and Preclinical Evidence for Cannabis as a Modulator of Feeding -- Alterations to Feeding Behavior Induced by Δ9-THC -- Alterations to Feeding Induced by Cannabis Extracts or Individual Phytocannabinoids -- The Role of Endogenous Cannabinoids in Feeding Behavior -- Overview of Clinical Eating Disorders. | |